Cargando…
Treatment adherence in hemophilia
Prophylactic clotting-factor regimens reduce the occurrence of bleeding episodes and maintain joint health in individuals with moderate and severe hemophilia. However, these outcomes are only achieved with adherence to prescribed prophylaxis regimens. There are several types of barriers to adherence...
Autores principales: | Thornburg, Courtney D, Duncan, Natalie A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630068/ https://www.ncbi.nlm.nih.gov/pubmed/29033555 http://dx.doi.org/10.2147/PPA.S139851 |
Ejemplares similares
-
Etranacogene dezaparvovec for hemophilia B gene
therapy
por: Thornburg, Courtney D.
Publicado: (2021) -
Evaluating Gene Therapy as a Potential Paradigm Shift in Treating Severe Hemophilia
por: Thornburg, Courtney D., et al.
Publicado: (2023) -
Gene Therapy for Hemophilia A: A Mixed Methods Study of Patient Preferences and Shared Decision-Making
por: Limjoco, Jacqueline, et al.
Publicado: (2023) -
Validation of the VERITAS-Pro treatment adherence scale in a Spanish sample population with hemophilia
por: Cuesta-Barriuso, Rubén, et al.
Publicado: (2017) -
Validation of the Brazilian version of the VERITAS-Pro scale to assess adherence to prophylactic regimens in hemophilia
por: Ferreira, Adriana Aparecida, et al.
Publicado: (2018)